The Effect of SGLT2 Inhibitor Dapagliflozin on BMI in Female Adolescents with Type 1 Diabetes

被引：0
|
作者：
Roman, R. [1 ]
Valdivia, N. [2 ]
Ruiz, S. [3 ]
机构：
[1] Univ Antofagasta, Hosp Reg Antofagasta, Antofagasta, Chile
[2] Univ Antofagasta, Antofagasta, Chile
[3] Hosp Reg Antofagasta, Antofagasta, Chile
来源：
HORMONE RESEARCH IN PAEDIATRICS | 2015年 / 84卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O15
引用
下载
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [1] RENOPROTECTIVE EFFECT OF SGLT2 INHIBITOR DAPAGLIFLOZIN IN TYPE-1 DIABETES
    Balogh, Dora
    Hodrea, Judit
    Lenart, Lilla
    Hosszu, Adam
    Szkibinszkij, Edgar
    Vannay, Adam
    Wagner, Laszlo
    Szabo, Attila
    Fekete, Andrea
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [2] Dapagliflozin, an SGLT2 inhibitor, for diabetes
    Hanefeld, Markolf
    Forst, Thomas
    LANCET, 2010, 375 (9733): : 2196 - 2198
  • [3] DAPAGLIFLOZIN, AN SGLT2 INHIBITOR FOR THE TREATMENT OF TYPE 2 DIABETES
    Demaris, K. M.
    White, J. R.
    DRUGS OF TODAY, 2013, 49 (05) : 289 - 301
  • [4] SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes
    Hodrea, Judit
    Saeed, Adar
    Molnar, Agnes
    Fintha, Attila
    Barczi, Adrienn
    Wagner, Laszlo J.
    Szabo, Attila J.
    Fekete, Andrea
    Balogh, Dora B.
    PLOS ONE, 2022, 17 (02):
  • [5] THE RENOPROTECTIVE EFFECT OF SODIUM-GLUCOSE COTRANSPORTER2 (SGLT2) INHIBITOR DAPAGLIFLOZIN IN TYPE 1 DIABETES
    Hodrea, Judit
    Lenart, Lilla
    Koszegi, Sandor
    Gellai, Renata
    Balogh, Dora B.
    Vannay, Adam
    Wagner, Laszlo J.
    Szabo, Attila J.
    Fekete, Andrea
    PEDIATRIC NEPHROLOGY, 2015, 30 (09) : 1633 - 1634
  • [6] Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes
    Nakamura, Yuta
    Nagai, Yoshio
    Terashima, Yuko
    Nishine, Ami
    Ishii, Satoshi
    Kato, Hiroyuki
    Ohta, Akio
    Tanaka, Yasushi
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (17) : 2553 - 2559
  • [7] Safety and efficacy of the SGLT2 inhibitor dapagliflozin in older patients with type 2 diabetes
    Fioretto, P.
    de Bruin, T. W.
    Johnsson, E.
    Ptaszynska, A.
    Parikh, S.
    List, J. F.
    DIABETOLOGIA, 2013, 56 : S383 - S383
  • [8] Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
    Yavin, Yshai
    Mansfield, Traci A.
    Ptaszynska, Agata
    Johnsson, Kristina
    Parikh, Shamik
    Johnsson, Eva
    DIABETES THERAPY, 2016, 7 (01) : 125 - 137
  • [9] Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
    Yshai Yavin
    Traci A. Mansfield
    Agata Ptaszynska
    Kristina Johnsson
    Shamik Parikh
    Eva Johnsson
    Diabetes Therapy, 2016, 7 : 125 - 137
  • [10] Effect of SGLT2 inhibitor dapagliflozin on skeletal muscle fatty acid metabolism in patients with type 2 diabetes
    Gemmink, A.
    op den Kamp, Y. J. M.
    de Ligt, M.
    Dautzenberg, B.
    Esterline, R.
    Hoeks, J.
    Schrauwen-Hinderling, V. B.
    Kersten, S.
    Havekes, B.
    Koves, T. R.
    Muio, D. M.
    Hesselink, M. K. C.
    Oscarsson, J.
    Phielix, E.
    Schrauwen, P.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S5 - S5
12345